Loading organizations...
InfaCare Pharmaceutical is a technology company.
InfaCare Pharmaceutical Corporation develops specialty drugs aimed at addressing critical unmet needs within neonatal and pediatric patient populations. The company focuses on creating pharmacological treatments for conditions like hyperbilirubinemia in infants, with its lead product, Stannsoporfin, designed to offer a dedicated solution for severe jaundice. Its technical approach emphasizes targeted therapies for vulnerable patients, including those with autoimmune and rare diseases, as well as specific neonatal respiratory and gastrointestinal issues.
Founded in 2001, InfaCare Pharmaceutical was established out of a recognized need for specialized pharmaceutical interventions for the youngest patients. The genesis of the company stemmed from an insight into the significant gaps in treatment options for various pediatric diseases, prompting a focused effort on drug development where existing therapies were insufficient or nonexistent.
InfaCare's products serve healthcare providers and hospitals treating neonates and children with specific medical conditions. The company's vision centers on pioneering novel pharmaceutical solutions to enhance health outcomes for this patient demographic. It strives to provide foundational pharmacological treatments for critical pediatric ailments, envisioning a future with improved therapeutic options for infant and child health.
InfaCare Pharmaceutical has raised $61.5M across 3 funding rounds.
InfaCare Pharmaceutical has raised $61.5M in total across 3 funding rounds.
InfaCare Pharmaceutical has raised $61.5M in total across 3 funding rounds.
InfaCare Pharmaceutical's investors include Atlas Venture, FirstMark Capital, HealthCare Ventures, Longitude Capital.
InfaCare Pharmaceutical Corporation is a specialty pharmaceutical company that develops and commercializes proprietary drugs for neonatal and pediatric patients, with its lead product stannsoporfin (Stanate) targeting hyperbilirubinemia, or severe infantile jaundice, in newborns at risk of neurological damage.[1][2][3] It serves neonatologists, pediatricians, and hospitals treating high-risk infants where phototherapy fails, addressing an unmet need as the only pharmacologic inhibitor of heme oxygenase in late-stage development to prevent bilirubin buildup.[1][3][4] Founded in 2005 and headquartered in Trevose, Pennsylvania, InfaCare raised $28 million in Series B financing in 2009 and was acquired by Mallinckrodt plc in 2017, advancing stannsoporfin toward potential commercialization after FDA Fast Track designation.[2][3][4]
InfaCare was founded in 2005 by Robert Vukovich, who serves as Chairman and recognized the potential of stannsoporfin years earlier to treat severe neonatal jaundice and its neurological risks.[2][3] Dan Burns led as President and CEO, overseeing development amid clinical milestones like treating over 1,200 neonates and a Phase 2B study expected in 2014.[1][3][4] Early traction included partnerships with drug manufacturers for GMP production and contract research organizations for preclinical/clinical studies, plus a $28 million Series B round in 2009 led by HealthCare Ventures, with investors like FirstMark Capital (formerly Pequot Ventures).[4] Pivotal moments were FDA Fast Track status in 2016 and Mallinckrodt's 2017 acquisition, fulfilling the founders' vision to bring the therapy to market.[3]
InfaCare rides the trend of specialty neonatology, addressing gaps in pediatric rare diseases amid rising focus on orphan drugs and precision therapies for vulnerable populations like preterm infants.[1][3] Timing aligned with FDA incentives like Fast Track for unmet needs, amid market forces favoring biologics/pharma acquisitions by larger players (e.g., Mallinckrodt's portfolio expansion).[3] It influences the ecosystem by validating heme oxygenase inhibition, spurring investment in neonatal biotech—evidenced by $28M Series B from health-focused VCs—and integrating into Mallinckrodt's specialty pharma pipeline.[2][3][4]
Post-2017 acquisition, InfaCare's stannsoporfin likely advanced toward approval under Mallinckrodt (now part of a broader pharma landscape), potentially launching as the first pharmacologic jaundice therapy and impacting thousands of at-risk newborns annually.[3] Trends like AI-driven trial design, gene therapies for neonates, and orphan drug pricing will shape progress, with Mallinckrodt's scale evolving its influence toward global neonatal care standards.[1][3] This positions it to transform outcomes in a niche long underserved by innovation.
InfaCare Pharmaceutical has raised $61.5M across 3 funding rounds. Most recently, it raised $3.5M Series C in March 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 21, 2013 | $3.5M Series C | Atlas Venture, FirstMark Capital, HealthCare Ventures, Longitude Capital | |
| Oct 1, 2008 | $28.0M Series B | Atlas Venture | |
| Mar 1, 2006 | $30.0M Series A | Atlas Venture |